Observational studyScientific reports2020
A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time.
Observational study in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A burden of proof study of the effects of exposure to high fasting plasma glucose on the risk of seven types of cancer.Scientific reports · 2025Pooled it
- Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis.Cancer medicine · 2023 · on this mapPooled it
- Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Review
- Observational
- A cross-sectional curvey study on the correlation between irrational drug use in diabetic patients and the occurrence of malignant tumors.Exploratory research in clinical and social pharmacy · 2026Article
- Medication Adherence and Risks of Mortality and End-Organ Damage in Asian Patients with Type 2 Diabetes: A Cohort Study from Southern Taiwan.Biomedicines · 2026Article
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- The Association Between Religiosity and Lifelong Cancer Incidence in an Israeli Male Cohort: A Competing Risk Survival Analysis.Epidemiologia (Basel, Switzerland) · 2026Article
- New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study.Diabetes, obesity & metabolism · 2026Article
- Stratifying high-risk prediabetes clusters using blood-based epigenetic markers.Biomarker research · 2026Article
- Lifetime risk of cancer in carriers of intermediate alleles in the HTT gene.Scientific reports · 2026Article
- Clinical Characteristics and Development of a Risk-Identification Model for Incidentally Detected Cancer in Patients with Diabetes: A Case-Control Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- A Retrospective Real-World Study: The Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer.Oncology research · 2026Article
- Nontraditional lipid and lipid-inflammatory parameters for risk stratification of abnormal glucose metabolism: a cross-sectional study in Chinese adults.Frontiers in endocrinology · 2026Article
- Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.Advances in therapy · 2025Article
- Associations of Type 2 Diabetes with Risk of Overall and Site-Specific Cancers in a Cohort of Predominantly Low-Income Racially Diverse Populations.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Hyperglycemia is associated with poor survival in patients with brain metastases treated with radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.Journal of clinical medicine · 2025Review
- GLP-1 receptor agonists in the context of cancer: the road ahead.American journal of physiology. Cell physiology · 2025 · on this mapReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined changing patterns in cancer incidence and deaths in diabetes compared to the background population. A total of 457,473 patients with type 2 diabetes, included between 1998 and 2014, were matched on age, sex, and county to five controls from the population. Incidence, trends in incidence and post-cancer mortality for cancer were estimated with Cox regression and standardised incidence rates. Causes of death were estimated using logistic regression. Relative importance of risk factors was estimated using Heller's relative importance model. Type 2 diabetes had a higher risk for all cancer, HR 1.10 (95% CI 1.09-1.12), with highest HRs for liver (3.31), pancreas (2.19) and uterine cancer (1.78). There were lesser increases in risk for breast (1.05) and colorectal cancers (1.20). Type 2 diabetes patients experienced a higher HR 1.23 (1.21-1.25) of overall post-cancer mortality and mortality from prostate, breast, and colorectal cancers. By the year 2030 cancer could become the most common cause of death in type 2 diabetes. Persons with type 2 diabetes are at greater risk of developing cancer and lower chance of surviving it. Notably, hazards for specific cancers (e.g. liver, pancreas) in type 2 patients cannot be explained by obesity alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.